PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 43.23 USD 0.79% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
PTC Therapeutics Inc?
Write Note

PTC Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PTC Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
PTC Therapeutics Inc
NASDAQ:PTCT
Pre-Tax Income
-$494.1m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
-23%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

PTC Therapeutics Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.

PTCT Intrinsic Value
45.53 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is PTC Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-494.1m USD

Based on the financial report for Jun 30, 2024, PTC Therapeutics Inc's Pre-Tax Income amounts to -494.1m USD.

What is PTC Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-23%

Over the last year, the Pre-Tax Income growth was 28%. The average annual Pre-Tax Income growth rates for PTC Therapeutics Inc have been -12% over the past three years , -18% over the past five years , and -23% over the past ten years .

Back to Top